

### Amendments to the Claims

Claim 1 (Currently amended): A recombinant cell line for assessing therapeutic agents that regulate apoptosis, comprising said recombinant cell line being stably transfected with:

- a) a first plasmid expressing a p300/CBP responsive promoter operably linked to a first reporter gene;
- b) a second plasmid expressing a non p300/CBP responsive promoter operably linked to a second reporter gene; and
- c) a third plasmid expressing a selectable marker gene.

Claim 2 (Currently amended): The cell line of claim 1, said cell line being further stably transfected with an additional plasmid encoding wild-type p300/CBP to augment endogenously expressed p300/CBP protein levels.

Claim 3 (Currently amended): A screening method for determining if a therapeutic ~~reagent~~ agent inhibits p300/CBP activity thereby inducing apoptosis, comprising:

- a) contacting recombinant cells with said therapeutic agent, said recombinant cells containing being stably transfected with:
  - i) a first plasmid expressing a p300/CBP responsive promoter operably linked to a first reporter gene;
  - ii) a second plasmid expressing a non p300/CBP responsive promoter operably linked to a second reporter gene; and
  - iii) a third plasmid expressing a selectable marker gene;
- b) assessing said recombinant cells for repression of the ~~p300/CBP responsive~~ first reporter gene by said therapeutic ~~reagent~~ agent; and

c) assessing said recombinant cells for repression of the ~~non-p300/CBP-responsive~~ second reporter gene by said therapeutic ~~reagent~~ agent, repression in step b) and not step c) indicating that the ~~compound~~ therapeutic agent inhibits p300/CBP ~~transactivation~~ activity and thereby induces apoptosis.

Claims 4-8 (cancelled)